セフポドキシム

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H317：アレルギー性皮膚反応を起こすおそれ

  H334：吸入するとアレルギー、喘息または、呼吸困難 を起こすおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P342+P311：呼吸に関する症状が出た場合：医師に連絡すること。

セフポドキシム 価格

セフポドキシム 化学特性,用途語,生産方法

• 効能

  抗生物質, 細胞壁合成阻害薬

• 化学的特性

  Off-White Solid

• 使用

  A metabolite of Cefpodoxime Proxetil. An antibacterial.

• 定義

  ChEBI: A third-generation cephalosporin antibiotic with methoxymethyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamino substituents at positions 3 and 7, respectively, of the cephem skeleton. Given by mouth as its proxetil ester prodrug, it is used to treat acute otitis media, pharyngitis, and sinusitis.

• 抗菌性

  It is stable to a wide range of plasmid-mediated β-lactamases. It induces the chromosomal β-lactamases of Ps. aeruginosa, Enterobacter spp., S. marcescens and Citrobacter spp., but is a less potent inducer than cefoxitin.

• 薬物動態学

  Oral absorption: c. 50%
  C_max 200 mg oral: 2.1 mg/L after 3 h
  Plasma half-life: c. 2.2 h
  Volume of distribution: c. 35 L
  Plasma protein binding: 20–30%
  Absorption and distribution
  The ester is rapidly hydrolyzed to the parent compound in the small intestine. Bioavailability increases to 65% if taken with food, but antacids and H2-receptor antagonists reduce absorption. Unabsorbed drug is hydrolyzed and excreted in the feces.
  It is well distributed and penetrates well into tissues (including lung tissue) and inflammatory exudate to achieve concentrations inhibitory to common pathogens.
  Metabolism and excretion
  The hydrolyzed prodrug is not subject to further metabolism. About 80% of the absorbed compound (30–40% of the original dose) appears in the urine over 24 h. Excretion is by glomerular filtration and tubular secretion; probenecid delays secretion and increases the peak plasma concentration.
  Metabolism and excretion
  The hydrolyzed prodrug is not subject to further metabolism. About 80% of the absorbed compound (30–40% of the original dose) appears in the urine over 24 h. Excretion is by glomerular filtration and tubular secretion; probenecid delays secretion and increases the peak plasma concentration.
  

• 臨床応用

  Cefpodoxime has been used principally for the treatment of upper and lower respiratory tract infections in children and adults.

• 副作用

  The drug is well tolerated, but gastrointestinal disturbance with diarrhea is common. Pseudomembranous colitis has been reported occasionally. Other side effects are those common to cephalosporins.

セフポドキシム 上流と下流の製品情報

セフポドキシム 生産企業

Global(138)Suppliers

セフポドキシム スペクトルデータ(¹HNMR)

80210-62-4, セフポドキシム キーワード